Opdivo Qvantig Alternatives Compared
| Opdivo Qvantig (hyaluronidase / nivolumab) | Opdivo (nivolumab) | Keytruda (pembrolizumab) |
|
|---|
| Opdivo Qvantig (hyaluronidase / nivolumab) | Opdivo (nivolumab) | Keytruda (pembrolizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Colorectal Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial... View more |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, and lung cancer. Fatigue, skin conditions, a cough, upper... View more |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Related suggestions Colorectal Cancer
|
|||||||||||||||||||||||
| More about Opdivo Qvantig (hyaluronidase / nivolumab) | More about Opdivo (nivolumab) | More about Keytruda (pembrolizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Opdivo has an average rating of 5.8 out of 10 from a total of 94 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 40% reported a negative effect. |
Keytruda has an average rating of 4.9 out of 10 from a total of 253 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 48% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Opdivo Qvantig side effects |
View all Opdivo side effects |
View all Keytruda side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Opdivo Qvantig prices |
View all Opdivo prices |
View all Keytruda prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
640.8 hours |
640.8 hours |
624 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 661 drugs are known to interact with Opdivo Qvantig:
|
A total of 588 drugs are known to interact with Opdivo:
|
A total of 588 drugs are known to interact with Keytruda:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 27, 2024 |
December 22, 2014 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.